# Pearl Index Study With Low Dose Combined Oral Contraceptive

> **NCT00220324** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 840 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** Minisiston (SH D00342A)

## Key facts

- **NCT ID:** NCT00220324
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 840 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220324, "Pearl Index Study With Low Dose Combined Oral Contraceptive". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00220324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*